Cigna invests in Bright Health’s $750M financing
Cigna Ventures and Bright's majority shareholder, New Enterprise Associates, are contributing to the financing. It comes as Bright faces higher-than-expected medical costs during the pandemic.
Monte Rosa raises $96M Series B for drug development platform technology
The Boston-based company plans to develop small-molecule therapeutics that go after historically "undruggable" targets using a process known as protein degradation.
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Black Diamond, targeting untapped cancer mutations, files for $100M IPO
Just a little over a year after it emerged from stealth mode, the company - which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors - has filed to go public.
Bright Health fuels expansion plans with $635M funding round
The insurance startup led by UnitedHealthcare’s former CEO closed a $635 million funding round led by New Enterprise Associates.
Elizabeth Warren calls on ex-FDA head Scott Gottlieb to resign from Pfizer’s board
In a letter addressed to Gottlieb, Warren implored him to resign from board of the Big Pharma company, writing "this kind of revolving door influence-peddling smacks of corruption."
Scott Gottlieb joins Pfizer board, but not everyone is celebrating
The announcement that the former Food and Drug Administration commissioner would join the pharma giant's board had many on social media criticizing what they saw as a revolving door between government and industry.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Scott Gottlieb returns to NEA – this time with some valuable regulatory experience under his belt
Gottlieb previously worked at NEA from 2007 to 2017, when he was appointed as commissioner of the FDA. He stepped down from that role in March, also returning to another previous employer, the American Enterprise Institute.
Black Diamond Therapeutics raises $85M in Series B funding
The raise comes a month after the Cambridge, Massachusetts-based firm's launch with a $20 million Series A round. Black Diamond is developing drugs that target allosteric mutant oncogenes, which it describes as an unexplored space.
The Medicines Co. spin-out Qpex launches with $33M in VC funding for antibiotics development
With New Enterprise Associates at the helm of the round, the company is setting out to develop antibiotics for drug-resistant bacterial infections.
Galera Therapeutics raises $150M Series C round to fund clinical development
The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.
presented by
3D Medical Animation Services: A Revolution in Healthcare Education and Marketing
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.
Curisium raises $3.5 million to enable value-based contracting via blockchain platform
The Manhattan Beach, California-based startup has raised $3.5 million in a seed round of funding from Green Bay Ventures, Sanofi Ventures, Flare Capital Partners and New Enterprise Associates.
Health insurance startup led by former UnitedHealthcare CEO raises $80M
Bessemer Ventures and New Enterprise Associates led Bright Health's Series A round. The company is led Bob Sheehy.
NEA participates in $35M round for British gene therapy player NightstaRx
New Enterprise Associates just led a $35 million Series B round for British gene therapy startup NightstaRx, which is developing a viral vector-based therapy for inherited vision loss.
Therachon, achondroplasia therapy developer, closes $35M Series A
Therachon has raised significant funding to support clinical proof of its soluable form of human fibroblast growth factor receptor 3. This could treat achondroplasia, a genetic mutation that is the leading cause of dwarfism.
Cartiva closes out $8M Series D to bring its synthetic cartilage product geared at osteoarthritis to U.S. market
Georgia medtech startup Cartiva just closed out an $8.5 million Series D, which will fund the company through PMA approval for its synthetic cartilage implant meant for those with osteoarthritis. It submitted a PMA application to the FDA just last month. The dollars will also fund Cartiva’s post-510(k) clinical trials on its ProxiFuse Hammertoe Correction System […]